Polypharmacy and the risks of long term use of antipsychotic medications point toward the need for identifying practices for deprescribing in psychiatry. The following article gives a brief overview of key points around deprescribing antipsychotic medications in psychiatry, including identifying risks and benefits, considerations around timing, and steps involved.. To read the full article, log in using your MPFT NHS OpenAthens details. SSOTP (legacy account) - You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Treatment-resistant schizophrenia (TRS) affects about one-third of individuals with schizophrenia. People with TRS do not experience sustained symptom relief and at the same time have the most severe disease-related disability and associated costs among individuals with severe mental disorders. Like caregivers of people with treatment-responsive schizophrenia, caregivers of individuals with TRS experience the disease burden along with their care recipients; however, for those providing care for individuals with TRS, the stress of the burden is unrelenting due to uncontrolled symptoms and a lack of effective treatment options. The objective of this study is to better understand the burden of TRS from the caregiver perspective and to explore their perception of available treatments.
Open access. Brain acetylcholine is decreased even in patients with cognitively preserved Parkinson’s disease (PD). We investigated whether early and long-term use of donepezil prevents psychosis in non-demented PD patients.
Open access. Hyperprolactinemia and glucose and lipid metabolism abnormalities are often found in patients with schizophrenia and are generally considered secondary to the use of antipsychotic drugs. More recent studies have shown these same neuroendocrine and metabolic abnormalities in antipsychotic naïve patients with first episode psychosis (FEP), rising the hypothesis that schizophrenia itself may be related to an abnormal regulation of prolactin secretion and to impaired glucose tolerance. The aim of this study was to compare prolactin levels, glycometabolism parameters and lipid profile between a sample of 31 drug-naive adolescents in the acute phase of FEP and a control group of 23 subjects at clinical high risk (CHR) of developing psychosis.
Open access. Schizophrenia (SCZ) is associated with increased risk of type 2 diabetes (T2D). The potential diabetogenic effect of concomitant application of psychotropic treatment classes in patients with SCZ has not yet been evaluated. The overarching goal of the Genetic Overlap between Metabolic and Psychiatric disease (GOMAP) study is to assess the effect of pharmacological, anthropometric, lifestyle and clinical measurements, helping elucidate the mechanisms underlying the aetiology of T2D.
Evidence from four RCTs suggests that bifeprunox may be effective in preventing global state deterioration and reducing positive and negative symptoms in adults with schizophrenia. However, evidence is of low to very low certainty, so no strong conclusions can be drawn.
Editorial. Login at top right hand side of page using your MPFT NHS OpenAthens for full text. SSOTP (legacy account)- Please contact the library to receive a copy of this article - http://bit.ly/1Xyazai
The high prevalence of smoking and cognitive deficits in schizophrenia patients is well known, but findings regarding the association between the two are contradictory, and longitudinal studies are lacking. The authors sought to examine the multi-cross-sectional association between smoking behavior and performance in specific cognitive domains and the longitudinal association between change in smoking behavior and change in cognitive functioning in a large prospective study.. Login at top right hand side of page using your MPFT NHS OpenAthens for full text. SSOTP (legacy account)- Please contact the library to receive a copy of this article - http://bit.ly/1Xyazai
This study tested for differences of white matter integrity between treated and never-treated long-term schizophrenia patients, matched on illness duration, and for differential changes in relation to age in these two groups relative to healthy comparison subjects.. Login at top right hand side of page using your MPFT NHS OpenAthens for full text. SSOTP (legacy account)- Please contact the library to receive a copy of this article - http://bit.ly/1Xyazai
Do 7-year-old children at familial high risk of schizophrenia spectrum disorders or bipolar disorder have neurocognitive impairments, and how do their neurocognitive profiles differ?. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai
Psychiatric Rehabilitation Journal (Jul 16, 2018). DOI:10.1037/prj0000309
Objective: Cognitive remediation (CR) is a promising method of improving cognitive functioning in people with schizophrenia. Nevertheless, the lived experience of participation, and whether this differs from computer game (CG) playing control conditions, remains poorly understood. This study aimed to qualitatively compare the experience of participating in these 2 interventions.. To read the full article, log in using your NHS OpenAthens details.
We're expanding our Be Aware updates and want to know what physical health topics you'd like to keep updated on. Let us know your ideas by replying to this email with 'physical health topics' followed by your suggestions
International treatment guidelines recommend cognitive-behavioral therapies for people with psychosis, but implementation remains problematic. This column reports on local work to improve implementation and two recent initiatives by the National Health Service in England. The aim is to operationalize key facilitators of implementation, including adequate training, time for delivery, and supervision; systems to identify the target caseload and monitor access, provision, and outcomes; effective pathways for offering and delivering therapy; and organizational support. With these facilitators in place, new investment translates readily into effective delivery. Still, achieving universal access to cognitive-behavioral therapies may require an alternative model.. Login at top right hand side of page using your MPFT NHS OpenAthens for full text. SSOTP (legacy account)- Please contact the library to receive a copy of this article - http://bit.ly/1Xyazai
Commentary on: Chou AIW, Wang Y-C, Lin C-L, et al. Female schizophrenia patients and risk of breast cancer: a population-based cohort study. Schizophrenia Research 2017;188:165–171.
What is already known on this topic
Research into rates of breast cancer in women with schizophrenia shows conflicting results, with reports of increased, decreased and the same risk as the general population. This is despite women with schizophrenia possibly being at increased risk of breast cancer through use of antipsychotic medications, many of which increase prolactin, a hormone involved in cellular differentiation of the mammary glands. This study1 investigated rates of breast cancer in individuals with schizophrenia compared with the general population.. To read the full article, log in using your NHS OpenAthens details.
Commentary on: Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry 2017;74:686–693.
What is already known on this topic
It is essential to identify differences in efficacy and effectiveness between antipsychotic options to inform treatment decisions in schizophrenia. Presence or absence of superiority has recently been particularly controversial for clozapine and long-acting injectable antipsychotics (LAIs), triggered by contrasting positive, negative and inconsistent meta-analyses of randomised controlled trials (RCTs).1–4 These inconsistencies may have been largely the result of selection bias since patients enrolled in RCTs may have a less severe illness, more insight, greater adherence and an overall better prognosis.4 This selection bias may be particularly important for clozapine and LAIs, which may be most effective in treatment-resistant patients and those with greater likelihood of non-adherence-related poor outcomes.. To read the full article, log in using your NHS OpenAthens details.
Commentary on : Bergman H, Walker DM, Nikolakopoulou A, et al. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess 2017;21:1-218.
What is already known on this topic
Tardive dyskinesia (TD) is a relatively frequent side effect of long-term use of antipsychotics and there is conflicting evidence if the incidence of TD is lower with second-generation antipsychotics (excluding clozapine), compared with first-generation antipsychotics. Until now there is no evidence-based algorithm to prevent or to treat TD.
Open access. It is time that all patients with acute-onset psychosis are screened for autoimmune encephalitis, that lumbar puncture becomes a routine psychiatric investigation and that immunotherapy is available in indicated cases. We call for a culture change in the management of psychosis by psychiatry.
It is important that nurses who work with individuals experiencing Serious Mental Illness (SMI) understand the assessment and management of specific communication, speech and language needs. You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
A nursing student reflects on the profound effect of taking time to share a meal with a patient with schizophrenia. You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
A. Laenen, T. Vangeneugden, H. Geys, and G. Molenberghs. The British journal of mathematical and statistical psychology, 59 (Pt 1):
113-31(May 2006)Mesures de concordància; Online; ICC; Psiquiatria.